Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Board Changes

5 Jan 2016 07:00

RNS Number : 7945K
Eland Oil & Gas PLC
05 January 2016
 

 

5th January 2016

 

Eland Oil & Gas PLC

("Eland" or the "Company")

 

 

Board Changes

 

Eland Oil & Gas PLC (AIM:ELA), the oil and gas production, development and exploration company operating in West Africa with a principal focus on Nigeria, announces today several changes to its Board of Directors.

 

With effect from 31 December 2015, Henry 'Harry' Wilson retired from his role as Chairman of the Company. Harry has been Chairman since its successful flotation in 2012 and was one of the founders.

 

The Company further announces that, with effect from 31 December 2015, Robert 'Bob' Lambert retired as Non-executive Director of the Company.

 

Also on that date, the Company appointed Grégory Stoupnitzky to the Board as a Non-executive Director. Gregory has over 25 years of Investment Banking experience in the natural resources and related sectors.

 

Harry Wilson, outgoing Chairman of the Company said:

 

"It has been a pleasure working with the team at Eland over the last five years. With the quality of its Nigerian assets, the Company is well positioned to benefit from an upswing in the oil price and I look forward to following its progress"

 

The Board of Eland also announces that Russell Harvey will be assuming the position of Non-executive Chairman of the Company. Russell has been a Non-executive Director of the Company since its admission on AIM in 2012.

 

Russell Harvey, incoming Chairman of the Company stated:

 

"I am pleased to assume the role of non-executive Chairman. The Company has made substantial progress since it was listed and has great potential for further growth given the established team and quality of its assets. The re-balancing of the Board is in response to the opportunities being created by the new market environment and to assist the Company in its next stage of development.

 

I would like to thank both Harry and Bob for their contributions which were pivotal in bringing the Company to its current producing status and wish them well in their future endeavours.

 

I would also like to welcome Grégory to the board. He brings a wealth of experience from the corporate and banking sector which will be additive to the skills already represented on the board."

 

 

Additional Information

 

Following the departure of Harry Wilson and Bob Lambert from the board of the Company and the appointment of Grégory Stoupnitzky, the committee structures will be revised as follows. Gregory will be appointed to the Nomination and Audit committees. The Audit committee will remain chaired by Henry Turcan with Russell Harvey assuming the chairmanship of the Reserves and Nomination committee while retaining his current chairmanship of the Remuneration committee.

 

In addition to his appointment as a director of the Company, Mr Grégory Alexis Stoupnitzky (aged 59) holds, or has held within the last five years, the following directorships or partnerships:

 

Current:

CIS Capital LLC

Graduate School of International and Public Affairs, Columbia University

 

Within the last five years:

Azonto Petroleum Limited

Rialto Energy Ltd.

Pace Financial Services

Vioco Petroleum Limited

Center for Energy, Marine Transportation and Public Policy, Columbia University

 

He held senior positions with Bear Stearns and Morgan Stanley and more recently, he worked with CIS Capital and Renaissance Capital providing advisory services to small companies and institutions involved with oil and gas in geographies including Sub-Saharan Africa. Gregory has a BA and an MA from Columbia University

 

There are no further disclosures to be made under Schedule 2g of the AIM Rules for Companies.

 

 

 

For further information:

Eland Oil & Gas PLC

+44 (0) 207 016 3180

George Maxwell, CEO

Louis Castro, CFO

Edward Cozens, IR

Canaccord Genuity Limited

+44 (0) 207 523 8000

Henry Fitzgerald-O'Connor

Wei Loon Yap

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAAKQDBCBKDQDK
Date   Source Headline
17th Jul 20095:57 pmBUSStudies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease
16th Jul 20092:18 pmRNSResults of Annual General Meeting
13th Jul 200911:30 amBUSElan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid
10th Jul 20094:59 pmRNSCancellation of UK Listing
8th Jul 20097:00 amBUSElan Announces Webcast of Second Quarter 2009 Financial Results
3rd Jul 200910:57 amRNSBlock Listing Six Monthly Return
2nd Jul 200912:57 pmRNSHolding in Company
2nd Jul 200912:41 pmPRNJohnson & Johnson, Elan Announce Definitive Agreement
1st Jun 20097:00 amBUSSubset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF? Therapy
29th May 20094:36 pmRNSPrice Monitoring Extension
29th May 20092:00 pmBUSRenee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer
29th May 200911:54 amBUSTotal Voting Rights
30th Apr 200912:16 pmBUSTotal Voting Rights
27th Apr 20093:35 pmRNSAnnual Report
14th Apr 20095:09 pmRNSHolding(s) in Company
27th Feb 20092:44 pmBUSTotal Voting Rights
25th Feb 200912:23 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
9th Feb 20097:00 amBUSMS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
4th Feb 20092:32 pmRNSHolding(s) in Company
3rd Feb 20093:57 pmRNSHolding(s) in Company
30th Jan 20094:33 pmRNSHolding(s) in Company
28th Jan 20094:24 pmRNSHolding(s) in Company
13th Jan 20097:00 amBUSElan Clarifies Duration of Bapineuzumab Phase 3 Trials
12th Jan 20095:21 pmRNSHolding(s) in Company
12th Jan 20097:00 amBUSTysabri Update
2nd Jan 200912:21 pmRNSTotal Voting Rights
18th Dec 20084:24 pmRNSBlock Listing Six Monthly Return
16th Dec 200811:00 amBUSDirector Declaration
16th Dec 20087:00 amBUSElan to Present at the 27th Annual JP Morgan Healthcare Conference
15th Dec 20083:02 pmBUSTysabri Update
12th Dec 20087:00 amBUSElan Announces Resource Realignment
28th Nov 200810:47 amBUSTotal Voting Rights
25th Nov 20087:00 amBUSMary Stutts to Join Elan as Senior Vice President and Head of Corporate Relations
20th Nov 20087:00 amBUSCarlos V. Paya, MD, PhD, to Join Elan as Company President
3rd Nov 20085:12 pmRNSDirector/PDMR Shareholding
31st Oct 20084:11 pmRNSHolding in Company
31st Oct 200812:01 pmRNSTotal Voting Rights
30th Oct 20084:13 pmRNSTysabri Update
3rd Oct 20085:56 pmRNSHolding in Company
30th Sep 20084:11 pmRNSTotal Voting Rights
22nd Sep 200811:26 amRNSHolding In Company
22nd Sep 20087:00 amRNSTysabri Demonstrates Sustained Improvement
11th Sep 20087:39 amRNSDirector /PDMR Shareholding
1st Sep 20085:02 pmRNSHolding(s) in Company
29th Aug 200810:54 amRNSTotal Voting Rights
28th Aug 20087:00 amRNSInterim Results
14th Aug 20084:12 pmRNSHolding in Company
13th Aug 20085:22 pmRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.